Research programme: monoclonal antibody-based therapeutics - Compugen

Drug Profile

Research programme: monoclonal antibody-based therapeutics - Compugen

Alternative Names: Antibody-based cancer immunotherapies - Compugen; Cancer immunotherapies - Compugen; CGEN 15027-targeted mAb; CGEN 15027-targeted monoclonal antibody; CGEN 15032-targeted immunotherapeutic; CGEN 15052-targeted mAb; CGEN 15052-targeted monoclonal antibody; CGEN 15137-targeted antibody; CGEN 15137/TIGIT; CGEN 671-targeted mAb; CGEN 671-targeted monoclonal antibody; CGEN XXXX; CGEN-15001T-targeted mAb; CGEN-15001T-targeted monoclonal antibody; CGEN-15022-targeted mAb; CGEN-15022-targeted monoclonal antibody; CGEN-15049-targeted mAb; CGEN-15049-targeted monclonal antibody; CGEN-928-targeted mAb; CGEN-928-targeted monoclonal antibody; COM 902; COM902/TIGIT; Immune checkpoint-targeted monoclonal antibodies - Compugen; Splice variant-targeted monoclonal antibody therapeutics - Compugen

Latest Information Update: 14 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Compugen
  • Class Monoclonal antibodies
  • Mechanism of Action B7 antigen inhibitors; CD28 antigen inhibitors; Immunomodulators; Membrane protein inhibitors; TIGIT protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Solid tumours
  • Research Haematological malignancies; Malignant melanoma; Multiple myeloma

Most Recent Events

  • 07 Aug 2017 Pharmacodynamics data from a preclinical study in Solid tumours released by Compugen
  • 02 Aug 2017 Bayer plans a phase I trial for CGEN 15001T programme
  • 26 Jul 2017 Bayer will return the rights to CGEN-15022 to Compugen
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top